Xilio Therapeutics (XLO) Competitors $0.76 -0.03 (-3.27%) Closing price 04:00 PM EasternExtended Trading$0.76 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock XLO vs. IPHA, ADCT, MOLN, CYBN, CCCC, SCPH, IVA, HURA, GLSI, and LRMRShould you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Innate Pharma (IPHA), ADC Therapeutics (ADCT), Molecular Partners (MOLN), Cybin (CYBN), C4 Therapeutics (CCCC), scPharmaceuticals (SCPH), Inventiva (IVA), TuHURA Biosciences (HURA), Greenwich LifeSciences (GLSI), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. Xilio Therapeutics vs. Innate Pharma ADC Therapeutics Molecular Partners Cybin C4 Therapeutics scPharmaceuticals Inventiva TuHURA Biosciences Greenwich LifeSciences Larimar Therapeutics Innate Pharma (NASDAQ:IPHA) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking. Does the media favor IPHA or XLO? In the previous week, Innate Pharma had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 4 mentions for Innate Pharma and 2 mentions for Xilio Therapeutics. Innate Pharma's average media sentiment score of 0.37 beat Xilio Therapeutics' score of -0.71 indicating that Innate Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Do analysts rate IPHA or XLO? Innate Pharma currently has a consensus target price of $11.50, suggesting a potential upside of 485.24%. Xilio Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 426.32%. Given Innate Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Innate Pharma is more favorable than Xilio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation and earnings, IPHA or XLO? Innate Pharma has higher revenue and earnings than Xilio Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnate Pharma$24.85M6.63-$8.19MN/AN/AXilio Therapeutics$6.34M6.20-$76.40M-$1.28-0.59 Is IPHA or XLO more profitable? Innate Pharma's return on equity of 0.00% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Innate PharmaN/A N/A N/A Xilio Therapeutics N/A -211.50%-80.31% Do insiders & institutionals have more ownership in IPHA or XLO? 0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in IPHA or XLO? Innate Pharma received 34 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Xilio Therapeutics an outperform vote while only 58.97% of users gave Innate Pharma an outperform vote. CompanyUnderperformOutperformInnate PharmaOutperform Votes4658.97% Underperform Votes3241.03% Xilio TherapeuticsOutperform Votes1275.00% Underperform Votes425.00% Which has more volatility and risk, IPHA or XLO? Innate Pharma has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.38, suggesting that its share price is 138% less volatile than the S&P 500. SummaryInnate Pharma beats Xilio Therapeutics on 13 of the 15 factors compared between the two stocks. Remove Ads Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XLO vs. The Competition Export to ExcelMetricXilio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.35M$6.99B$5.68B$8.30BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-0.447.2324.5519.25Price / Sales6.20230.77395.7294.10Price / CashN/A65.6738.1634.64Price / Book0.576.617.064.46Net Income-$76.40M$142.13M$3.19B$247.07M7 Day Performance-1.94%2.79%1.49%3.05%1 Month Performance-14.70%2.70%5.87%-2.85%1 Year Performance8.59%-4.42%14.94%4.63% Xilio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XLOXilio Therapeutics3.0437 of 5 stars$0.76-3.3%$4.00+426.3%+11.1%$39.35M$6.34M-0.4470News CoverageIPHAInnate Pharma2.3095 of 5 stars$1.94-5.1%$11.50+494.3%-18.4%$162.21M$24.85M0.00220Upcoming EarningsNews CoverageADCTADC Therapeutics1.6927 of 5 stars$1.67+3.4%$8.50+410.5%-63.3%$160.99M$70.72M-0.70310MOLNMolecular Partners1.5542 of 5 stars$3.97+0.9%$12.00+202.6%-2.5%$160.09M$4.97M-1.84180CYBNCybin2.7879 of 5 stars$7.38+1.0%$86.00+1,065.3%N/A$158.50MN/A-1.6850CCCCC4 Therapeutics1.7476 of 5 stars$2.22+4.7%$12.50+463.1%-73.0%$157.60M$35.58M-1.31150SCPHscPharmaceuticals3.5874 of 5 stars$3.13+4.3%$14.00+347.3%-39.5%$157.39M$36.33M-1.6530Earnings ReportIVAInventiva1.4736 of 5 stars$2.92+3.5%$12.60+331.5%-24.0%$153.23M$15.62M0.00100Upcoming EarningsNews CoverageHURATuHURA BiosciencesN/A$3.59+7.8%$13.00+262.1%N/A$151.80MN/A0.00N/AUpcoming EarningsHigh Trading VolumeGLSIGreenwich LifeSciences1.6316 of 5 stars$11.25+1.3%$38.00+237.8%-42.7%$147.88MN/A-14.063LRMRLarimar Therapeutics2.3636 of 5 stars$2.28-10.2%$20.13+782.7%-71.8%$145.48MN/A-1.9830Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume Remove Ads Related Companies and Tools Related Companies IPHA Competitors ADCT Competitors MOLN Competitors CYBN Competitors CCCC Competitors SCPH Competitors IVA Competitors HURA Competitors GLSI Competitors LRMR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XLO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
